All In Biotech

Drug Trial Radar · NCT05985655

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jul 6, 2023

Primary completion

Jan 2028

Study completion May 2028

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pancreatic Adenocarcinoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
  • Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
  • Triple Negative Breast Cancer (TNBC)

Interventions

  • GTAEXS617Drug

    Administered as specified in the treatment arm.

  • SoCDrug

    Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 2 years
  2. Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  3. Phase 2 : Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Up to 2 years

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • GZA Ziekenhuizen - Campus Sint-Augustinus

    Antwerp, Belgium · Recruiting

  • Clinique Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • Institute Jules Bordet

    Brussels, Belgium · Recruiting

  • CHU Sart Tilman

    Liège, Belgium · Recruiting

  • The Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Recruiting

  • UCL Hospitals NHS Foundation Trust

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Newcastle Upon Tyne NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.